BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, in vitro anti-α-glucosidase evaluations, and computational studies of new phthalimide-phenoxy-1,2,3-triazole-N-phenyl (or benzyl) acetamides as potential anti-diabetic agents. 2023

Mehdi Emadi, and Mohammad Halimi, and Ali Moazzam, and Samanesadat Hosseini, and Somayeh Mojtabavi, and Mohammad Ali Faramarzi, and Reza Ghadimi, and Ali Akbar Moghadamnia, and Ensieh Nasli-Esfahani, and Maryam Mohammadi-Khanaposhtani, and Mohammad Mahdavi
Electrical and Computer Engineering Department, Babol Noshirvani University of Technology, Babol, Iran.

An important target in the treatment of type 2 diabetes is α-glucosidase. Inhibition of this enzyme led to delay in glucose absorption and decrease in postprandial hyperglycemia. A new series of phthalimide-phenoxy-1,2,3-triazole-N-phenyl (or benzyl) acetamides 11a-n were designed based on the reported potent α-glucosidase inhibitors. These compounds were synthesized and screened for their in vitro inhibitory activity against the latter enzyme. The majority of the evaluated compounds displayed high inhibition effects (IC50 values in the range of 45.26 ± 0.03-491.68 ± 0.11 µM) as compared to the positive control acarbose (IC50 value = 750.1 ± 0.23 µM). Among this series, compounds 11j and 11i represented the most potent α-glucosidase inhibitory activities with IC50 values of 45.26 ± 0.03 and 46.25 ± 0.89 µM. Kinetic analysis revealed that the compound 11j is a competitive inhibitor with a Ki of 50.4 µM. Furthermore, the binding interactions of the most potent compounds in α-glucosidase active site were studied through molecular docking and molecular dynamics. The latter studies confirmed the obtained results through in vitro experiments. Furthermore, in silico pharmacokinetic study of the most potent compounds was also performed.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007700 Kinetics The rate dynamics in chemical or physical systems.
D010797 Phthalimides The imide of phthalic acids.
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D000520 alpha-Glucosidases Enzymes that catalyze the exohydrolysis of 1,4-alpha-glucosidic linkages with release of alpha-glucose. Deficiency of alpha-1,4-glucosidase may cause GLYCOGEN STORAGE DISEASE TYPE II. Acid Maltase,Lysosomal alpha-Glucosidase,Maltase,Maltases,Maltase-Glucoamylase,Neutral Maltase,Neutral alpha-Glucosidase,alpha-Glucosidase,Lysosomal alpha Glucosidase,Maltase Glucoamylase,Neutral alpha Glucosidase,alpha Glucosidase,alpha Glucosidases,alpha-Glucosidase, Lysosomal,alpha-Glucosidase, Neutral
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Mehdi Emadi, and Mohammad Halimi, and Ali Moazzam, and Samanesadat Hosseini, and Somayeh Mojtabavi, and Mohammad Ali Faramarzi, and Reza Ghadimi, and Ali Akbar Moghadamnia, and Ensieh Nasli-Esfahani, and Maryam Mohammadi-Khanaposhtani, and Mohammad Mahdavi
Indole-carbohydrazide linked phenoxy-1,2,3-triazole-N-phenylacetamide derivatives as potent α-glucosidase inhibitors: design, synthesis, in vitro α-glucosidase inhibition, and computational studies.
June 2023, BMC chemistry,
Mehdi Emadi, and Mohammad Halimi, and Ali Moazzam, and Samanesadat Hosseini, and Somayeh Mojtabavi, and Mohammad Ali Faramarzi, and Reza Ghadimi, and Ali Akbar Moghadamnia, and Ensieh Nasli-Esfahani, and Maryam Mohammadi-Khanaposhtani, and Mohammad Mahdavi
Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro α-glucosidase inhibition, kinetic, and docking studies.
November 2019, Bioorganic chemistry,
Mehdi Emadi, and Mohammad Halimi, and Ali Moazzam, and Samanesadat Hosseini, and Somayeh Mojtabavi, and Mohammad Ali Faramarzi, and Reza Ghadimi, and Ali Akbar Moghadamnia, and Ensieh Nasli-Esfahani, and Maryam Mohammadi-Khanaposhtani, and Mohammad Mahdavi
Design and synthesis of 4,5-diphenyl-imidazol-1,2,3-triazole hybrids as new anti-diabetic agents: in vitro α-glucosidase inhibition, kinetic and docking studies.
May 2021, Molecular diversity,
Mehdi Emadi, and Mohammad Halimi, and Ali Moazzam, and Samanesadat Hosseini, and Somayeh Mojtabavi, and Mohammad Ali Faramarzi, and Reza Ghadimi, and Ali Akbar Moghadamnia, and Ensieh Nasli-Esfahani, and Maryam Mohammadi-Khanaposhtani, and Mohammad Mahdavi
Design and synthesis of novel quinazolinone-1,2,3-triazole hybrids as new anti-diabetic agents: In vitro α-glucosidase inhibition, kinetic, and docking study.
March 2019, Bioorganic chemistry,
Mehdi Emadi, and Mohammad Halimi, and Ali Moazzam, and Samanesadat Hosseini, and Somayeh Mojtabavi, and Mohammad Ali Faramarzi, and Reza Ghadimi, and Ali Akbar Moghadamnia, and Ensieh Nasli-Esfahani, and Maryam Mohammadi-Khanaposhtani, and Mohammad Mahdavi
Design, synthesis, in vitro, and in silico evaluations of benzo[d]imidazole-amide-1,2,3-triazole-N-arylacetamide hybrids as new antidiabetic agents targeting α-glucosidase.
July 2023, Scientific reports,
Mehdi Emadi, and Mohammad Halimi, and Ali Moazzam, and Samanesadat Hosseini, and Somayeh Mojtabavi, and Mohammad Ali Faramarzi, and Reza Ghadimi, and Ali Akbar Moghadamnia, and Ensieh Nasli-Esfahani, and Maryam Mohammadi-Khanaposhtani, and Mohammad Mahdavi
Synthesis and biological evaluation of a new series of benzofuran-1,3,4-oxadiazole containing 1,2,3-triazole-acetamides as potential α-glucosidase inhibitors.
April 2021, Journal of biochemical and molecular toxicology,
Mehdi Emadi, and Mohammad Halimi, and Ali Moazzam, and Samanesadat Hosseini, and Somayeh Mojtabavi, and Mohammad Ali Faramarzi, and Reza Ghadimi, and Ali Akbar Moghadamnia, and Ensieh Nasli-Esfahani, and Maryam Mohammadi-Khanaposhtani, and Mohammad Mahdavi
N-benzyl-4-phenyl-1,2,3-triazole derivatives as in vitro inhibitors of the prostaglandin synthesis.
August 1986, Il Farmaco; edizione scientifica,
Mehdi Emadi, and Mohammad Halimi, and Ali Moazzam, and Samanesadat Hosseini, and Somayeh Mojtabavi, and Mohammad Ali Faramarzi, and Reza Ghadimi, and Ali Akbar Moghadamnia, and Ensieh Nasli-Esfahani, and Maryam Mohammadi-Khanaposhtani, and Mohammad Mahdavi
Synthesis, in vitro and computational studies of 1,4-disubstituted 1,2,3-triazoles as potential α-glucosidase inhibitors.
February 2016, Bioorganic & medicinal chemistry letters,
Mehdi Emadi, and Mohammad Halimi, and Ali Moazzam, and Samanesadat Hosseini, and Somayeh Mojtabavi, and Mohammad Ali Faramarzi, and Reza Ghadimi, and Ali Akbar Moghadamnia, and Ensieh Nasli-Esfahani, and Maryam Mohammadi-Khanaposhtani, and Mohammad Mahdavi
Design, synthesis, in vitro, and in silico biological evaluations of coumarin-indole hybrids as new anti-α-glucosidase agents.
November 2022, BMC chemistry,
Mehdi Emadi, and Mohammad Halimi, and Ali Moazzam, and Samanesadat Hosseini, and Somayeh Mojtabavi, and Mohammad Ali Faramarzi, and Reza Ghadimi, and Ali Akbar Moghadamnia, and Ensieh Nasli-Esfahani, and Maryam Mohammadi-Khanaposhtani, and Mohammad Mahdavi
Design, synthesis, in vitro, and in silico studies of novel diarylimidazole-1,2,3-triazole hybrids as potent α-glucosidase inhibitors.
December 2019, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!